Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
J Clin Pharm Ther
; 46(2): 440-446, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: covidwho-887386
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
The coronavirus disease 2019 (COVID-19) associated cytokine activation can lead to a rapid progression into respiratory failure, shock and multiorgan failure. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that likely contributes to the pathogenesis of cytokine release syndrome. It is hypothesized that modulating IL-6 levels or its effects with tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody, may alter the course of disease.METHODS:
We examined the association between tocilizumab use and intubation or death at a community hospital in New York City. Data were obtained regarding consecutive patients hospitalized with COVID-19. The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received tocilizumab with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS ANDDISCUSSION:
In this single-centre retrospective cohort study involving 1225 hospitalized patients with SARS-CoV-2 infection, the probability to respiratory failure, which was measured as intubation or death, was less frequent in patients who received tocilizumab. WHAT IS NEW ANDCONCLUSION:
Tocilizumab and other IL-6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID-19.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Respiración Artificial
/
Interleucina-6
/
Anticuerpos Monoclonales Humanizados
/
Síndrome de Liberación de Citoquinas
/
SARS-CoV-2
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio de cohorte
/
Estudios diagnósticos
/
Estudio observacional
/
Estudio pronóstico
Límite:
Femenino
/
Humanos
/
Masculino
/
Middle aged
País/Región como asunto:
America del Norte
Idioma:
Inglés
Revista:
J Clin Pharm Ther
Asunto de la revista:
Farmacia
/
Terapeutica
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Jcpt.13303
Similares
MEDLINE
...
LILACS
LIS